Reversible Posterior Leukoencephalopathy Syndrome After Bevacizumab/FOLFIRI Regimen for Metastatic Colon Cancer

Jeffrey A. Allen, MD; Ashish Adlakha, MD; Peter R. Bergethon, MD

Objective: To describe a patient with reversible posterior leukoencephalopathy syndrome following the administration of bevacizumab (Avastin), a monoclonal antibody against vascular endothelial growth factor.

Design: Case report/literature review.

Setting: University hospital.

Patient: A 52-year-old man receiving chemotherapy for stage IV rectal carcinoma.

Results: Clinical and radiographic evidence consistent with reversible posterior leukoencephalopathy syndrome was found following the administration of irinotecan hydrochloride, leucovorin calcium, and fluorouracil (FOLFIRI) regimen chemotherapy and bevacizumab.

Conclusions: Reversible posterior leukoencephalopathy syndrome following treatment with angiogenesis modulators can occur. In addition to raising clinical suspicion in appropriate patients, this report may yield clues to the pathophysiologic underpinnings of reversible posterior leukoencephalopathy syndrome.

Arch Neurol. 2006;63:1475-1478
was normal; serum urea nitrogen and creatinine levels were also measured, liver function testing was performed, and a peripheral blood smear was obtained. On day 17, the patient developed transcortical global aphasia with intermittent spells of confusion and agitation. By day 18, his speech and visual disturbance began to improve. On day 19, he experienced a generalized tonic-clonic seizure. A diagnostic lumbar puncture showed a normal opening pressure and normal cerebrospinal microscopic and biochemistry results. Subsequent magnetic resonance imaging on day 19 showed interval improvement in fluid-attenuated inversion recovery hyperintensities (Figure 2). By day 25, the patient’s neurologic deficits had completely resolved.

Over the next 6 weeks, the patient developed new bony lesions involving the thoracic and lumbar vertebrae, with cord compression. Treatment was initiated with corticosteroids and palliative radiation. No further chemotherapy cycles were given, and no further neurologic spells occurred.

**COMMENT**

The onset and resolution of cortical blindness and seizure activity observed in our patient correlated with the radiographic abnormalities and were consistent with the natural history of RPLS. The focal nature and immediate onset of our patient’s visual disturbance might suggest that an ischemic event had occurred. However, imaging studies pointed to vasogenic edema as the chief cause, rather than infarction. Furthermore, the patient’s clinical improvement correlated with radiographic occipital lobe edema resolution. Although not entirely understood, the mechanism of RPLS is considered to be secondary to failed autoregulation of cerebral blood flow leading to cerebral vasogenic edema. Failed cerebral vascular autoregulation results in hyperperfusion and dilation of cerebral arterioles, disruption of the endothelium, immediate breakdown of the blood-brain barrier, and, finally, transudation of plasma and red blood cells into the interstitium. A relative paucity of sympathetic adrenergic innervation to the vertebral-basilar system is suggested to account for the tendency for this syndrome to involve structures supplied by the posterior circulation. Hypointense T1 lesions and hyperintense T2 lesions are often seen bilaterally in occipital and parietal lobe white matter. Predisposing factors consistent with this proposed mechanism of vascular dysregulation have been described by Tam and colleagues, who regard patients with significant fluid overload (>10% of the baseline weight), a mean blood pressure higher than 25% of baseline, and a creatinine level greater than 1.8 mg/dL (>160 µmol/L) to be high risk for RPLS.

Toxic damage to the vascular endothelium or blood-brain barrier caused by immunosuppressant and cytotoxic medications is further postulated to contribute to the pathophysiological features of RPLS. Direct causal relationships between chemotherapy agents and RPLS have been difficult to establish, and the correlation is more common with cyclosporine and tacrolimus. Other associated agents include methotrexate; the alpha
interferons; cisplatin; cytarabine; cyclophosphamide, doxorubicin hydrochloride (Adriamycin), vincristine sulfate (Oncovin), and prednisone; or combinations involving doxorubicin, ifosfamide, and etoposide. While we cannot be certain of the causal relationship between bevacizumab and the RPLS in our patient, it seems most likely by the following process of elimination: the chemotherapeutic regimen in our patient also consisted of FOLFIRI. The cerebral toxicity of fluorouracil, although rare, is well described as a multifocal inflammatory leukoencephalopathy. Multifocal inflammatory leukoencephalopathy typically develops 6 weeks to 5 months after the initiation of combination chemotherapy with leucovorin hydrochloride and fluorouracil. Multifocal inflammatory leukoencephalopathy is a clinically and radiographically distinct syndrome from RPLS, making it unlikely that fluorouracil caused our patient’s syndrome. To our knowledge, no reports in the literature associate irinotecan, a type I topoisomerase inhibitor, with the development of RPLS or other encephalopathy syndromes. Leucovorin, a derivative of folic acid, would not be expected to contribute to the development of RPLS. During the review of this report, several other investigators observed an association between RPLS and bevacizumab administration.

Bevacizumab, a monoclonal antibody against VEGF, has recently been approved as a first-line treatment for patients with metastatic colorectal cancer when administered in combination with FOLFIRI. Vascular endothelial growth factor is a naturally occurring, endothelial, cell-specific glycoprotein that stimulates blood vessel formation and has been implicated in tumor growth and spread. Nitric oxide and prostacyclin production are enhanced by VEGF, thus promoting vasodilation. The effects of VEGF inhibition on the systemic endothelium have been described. Soluble fms-like tyrosine kinase 1 is a naturally occurring VEGF antagonist expressed by the placenta and is thought to produce an antiangiogenic state by binding VEGF and placental growth factor. Vascular endothelial growth factor and placental growth factor bound to soluble fms-like tyrosine kinase 1 render them biologically inactive, thus inducing endothelial cell dysfunction. Animal studies by Sugimoto and colleagues demonstrated that administration of anti-VEGF antibodies and soluble fms-like tyrosine kinase 1 resulted in glomerular endothelial cell detachment and hypertrophy. The resulting glomerular endotheliosis has been suggested to be responsible for the hypertension and proteinuria commonly seen in preeclamptic patients. Furthermore, alterations in angiogenic factors have been postulated to disrupt normal systemic endothelial cell function and increase the cerebral vascular permeability of the blood-brain barrier, thus contributing to RPLS in preeclamptic patients.

Bevacizumab is a potent inhibitor of VEGF function, disrupting angiogenesis and depriving tumors of their blood supply. Angiogenesis inhibitors are thought to be beneficial in cancer treatment by normalizing pathologic tumor vasculature and restoring proangiogenic and antiangiogenic factors and, thereby, allowing for more efficient delivery of chemotherapeutic agents to tumors. Hypertension and proteinuria are commonly reported adverse effects of bevacizumab. We suggest that the development of RPLS in our patient may have been secondary to bevacizumab. Several mechanisms may be contributory. First, bevacizumab may have contributed to the patient’s hypertensive state in an otherwise nonhypertensive patient, because hypertensive crises are known adverse effects of this medication. Although our patient had a mean blood pressure higher than 25% of baseline, he was not otherwise at high risk for the development of RPLS. He was not hypervolemic, and his serum creatinine level was normal. Second, a global endothelial cell dysfunction induced by bevacizumab may have led to RPLS. Although microangiopathic hemo-lytic anemia was not suggested by our patient’s blood smear result, hypertension and proteinuria were present. We speculate that inhibition of VEGF induced systemic endothelial cell dysfunction and, in particular, that of the cerebral vasculature, which, when exposed to moderately elevated perfusion, was unable to appropriately accommodate. The induction of RPLS in our patient and possibly in preeclamptic patients may be secondary to this mechanism.

We postulate that the RPLS in our patient resulted from systemic endothelial cell dysfunction induced by bevacizumab. A more detailed understanding of the mechanism of VEGF modulators on the cerebral vasculature is needed. Regardless, high clinical suspicion is encouraged toward patients presenting with symptoms characteristic of RPLS while receiving bevacizumab, particularly when in combination with FOLFIRI therapy. Prompt recognition of this syndrome will allow initiation of immediate treatment and appropriate alterations in chemotherapy regimens.

Accepted for Publication: May 15, 2006.
Correspondence: Peter R. Bergethon, MD, Department of Anatomy and Neurobiology, Boston University School of Medicine, 715 Albany St, Boston, MA 02118 (prberget@bu.edu).

Author Contributions: Study concept and design: Allen and Bergethon. Acquisition of data: Allen. Analysis and interpretation of data: Allen, Adlakha, and Bergethon. Drafting of the manuscript: Allen, Adlakha, and Bergethon. Critical revision of the manuscript for important intellectual content: Allen, Adlakha, and Bergethon. Administrative, technical, and material support: Allen and Bergethon. Study supervision: Bergethon.

REFERENCES


**Announcement**

**Trial Registration Required.** In concert with the International Committee of Medical Journal Editors (ICMJE), Archives of Neurology will require, as a condition of consideration for publication, registration of all trials in a public trials registry (such as http://ClinicalTrials.gov). Trials must be registered at or before the onset of patient enrollment. This policy applies to any clinical trial starting enrollment after July 1, 2005. For trials that began enrollment before this date, registration will be required by September 13, 2005, before considering the trial for publication. The trial registration number should be supplied at the time of submission.

For details about this new policy, and for information on how the ICMJE defines a clinical trial, see the editorial by DeAngelis et al in the January issue of Archives of Dermatology (2005;141:76-77). Also see the Instructions to Authors on our Web site: www.archneurol.com.